Economic Implications of Direct Thrombin Inhibitors in the Cath Lab
Paper Symposium
Activity Date: July 2005  — Activity Info: Volume 2, (3)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired) | Order Copy of Activity


Full Disclosure Policy Affecting CE Activities:
As a sponsor accredited by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:


L. Brian Cross, PharmD, CDE
Assistant Professor
University of Tennessee
Health Science Center
Colleges of Pharmacy & Medicine
Director of Pharmacotherapy Services
UT St. Francis Family Practice Center
Memphis, Tennessee
Dr Cross reports receiving grants/research support from AstraZeneca LP, Pfizer Inc, Roche Diagnostics, Sanofi-Aventis, and The Medicines Company; serving as a consultant to AstraZeneca LP and Pfizer Inc; and receiving honoraria from Pfizer Inc.


David J. Cohen, MD, MSc
Associate Professor of Medicine
Cardiovascular Division
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dr Cohen reports receiving grants/research support from The Medicines Company.
Ann K. Wittkowsky, PharmD, CACP, FASHP
Clinical Professor of Pharmacy
University of Washington School of Pharmacy
Director of Anticoagulation Services
University of Washington Medical Center
Seattle, Washington
Dr Wittkowsky reports serving as a consultant to AstraZeneca LP, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharmaceuticals USA, Sanofi-Aventis, and The Medicines Company.

Notice: In accordance with the ACPE Criteria for Quality, the audience is advised that one or more articles in this continuing pharmaceutical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. The following faculty members have disclosed that their articles have referenced the following unlabeled/unapproved uses of drugs or devices:

Dr Cohen—ximelagatran.

All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

Home | Contact Us | View Account | Need Help?